Top

Archives of Orthopaedic and Trauma Surgery

Published in:

01-12-2011 | Knee Arthroplasty

Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty

Authors: Doerte Matziolis, Georg Matziolis, Carsten Perka

Published in: Archives of Orthopaedic and Trauma Surgery | Issue 12/2011

Abstract

Introduction

Low-molecular-weight heparins (LMWH) are commonly used in thrombosis prophylaxis after total knee arthroplasty. In contrast to LMWH, dabigatran etexilate is an oral and direct acting anticoagulant. The hypothesis of the present study was that blood loss occurring in total knee arthroplasty (TKA) is not greater after dabigatran etexilate than after dalteparin.

Method

All patients suffering from primary arthrosis of knee joint that had received a total knee arthroplasty were included in this retrospective case–control study. Two groups were formed (dalteparin versus dabigatran etexilate) and the perioperative blood loss was compared using the formula of Nadler (V = EBV × ln (Hct₀/Hct₁) [V = blood loss (l); EBV = blood volume (l); Hct₀ = preoperative haematocrit; Hct₁ = haematocrit on the first postoperative day].

Patients: A total of 155 patients, 61 men and 94 women, were included. The calculated blood loss differed significantly between the two groups. The blood loss was on average 1.5 ± 0.58 l [0.32–2.9 l] in the dalteparin group, compared with 1.3 ± 0.63 l [0.29–4.31 l] in the dabigatran etexilate group (p < 0.01). None of the patients of both observed groups showed clinical signs of thrombosis or pulmonary artery embolism.

Results

Dabigatran etexilate showed a lower perioperative blood loss than dalteparin by comparable safety of both drugs.

Conclusion

Whether the timing of administration or pharmacological factors were responsible for this cannot be explained by our study.

White RH, Zhou H, Romano PS (2003) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90(3):446–455PubMed

White RH, Romano PS, Zhou H, Rodrigo J, Bargar W (1998) Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 158(14):1525–1531PubMedCrossRef

Encke A, Haas S, Sauerland S (2009) S3 - Leitlinie - Prophylaxe der venösen Thrombembolie (VTE). VASA 38(Suppl.):1–132CrossRef

Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):204S–233SPubMedCrossRef

Hirsh J, O’Donnell M, Eikelboom JW (2007) Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116(5):552–560PubMedCrossRef

Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S–400SPubMedCrossRef

Stern SH, Wixson RL, O’Connor D (2000) Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. J Arthroplasty 15(2):153–158PubMedCrossRef

Novotny J, Konvickova L (1998) Heparin-induced thrombocytopenia. Vnitr Lek 44(5):282–287PubMed

Mendez J, Sanchis ME, de la FR, Stolle R, Vega JM, Martinez C et al (1998) Delayed-type hypersensitivity to subcutaneous enoxaparin. Allergy 53(10):999–1003

10.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11):2178–2185PubMedCrossRef

11.

Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI (2009) Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 101(1):77–85PubMed

12.

Baetz BE, Spinler SA (2008) Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28(11):1354–1373PubMedCrossRef

13.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591):949–956PubMedCrossRef

14.

15.

Eriksson BI, Friedman R (2009) Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost

16.

17.

Stangier J, Rathgen K, Stähle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Pharmacol 64:292–303CrossRef

18.

Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47:285–295PubMedCrossRef

19.

Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399PubMedCrossRef

20.

Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W (2009) Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 9:59–68PubMed

21.

(2000) Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medical products for prophylaxis of intra- and postoperative venous thromboembolic risk. London: The European Agency for the Evaluation of Medicinal Products

22.

Bergqvist D (2004) Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. Eur J Haematol 73(4):227–242PubMedCrossRef

23.

24.

Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24(1):1–9PubMedCrossRef

25.

Nadler SB, Hidalgo JU, Bloch T (1962) Prediction of blood volume in normal human adults. Surgery 51:224–232PubMed

26.

Baetz BE, Spinler SA (2008) Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28(11):1354–1373PubMedCrossRef

27.

28.

Sehat KR, Evans R, Newman JH (2000) How much blood is really lost in total knee arthroplasty?. Correct blood loss management should take hidden loss into account. Knee 7(3):151–155PubMedCrossRef

29.

Bell TH, Berta D, Ralley F, Macdonald SJ, McCalden RW, Bourne RB et al (2009) Factors affecting perioperative blood loss and transfusion rates in primary total joint arthroplasty: a prospective analysis of 1642 patients. Can J Surg 52(4):295–301PubMed

30.

Baetz BE, Spinler SA (2008) Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28(11):1354–1373PubMedCrossRef

31.

Raskob GE, Hirsh J (2003) Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 124(6 Suppl):379S–385SPubMedCrossRef

32.

Bjornara BT, Gudmundsen TE, Dahl OE (2006) Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 88(3):386–391PubMedCrossRef

33.

Strebel N, Prins M, Agnelli G, Buller HR (2002) Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 162(13):1451–1456PubMedCrossRef

34.

Hull RD, Pineo GF, MacIsaac S (2001) Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res 101(1):V155–V162PubMedCrossRef

35.

Juelsgaard P, Larsen UT, Sorensen JV, Madsen F, Soballe K (2001) Hypotensive epidural anesthesia in total knee replacement without tourniquet: reduced blood loss and transfusion. Reg Anesth Pain Med 26(2):105–110PubMed

36.

Sharrock NE, Hargett MJ, Urquhart B, Peterson MG, Ranawat C, Insall J et al (1993) Factors affecting deep vein thrombosis rate following total knee arthroplasty under epidural anesthesia. J Arthroplasty 8(2):133–139PubMedCrossRef

37.

Meunier A, Lisander B, Good L (2007) Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Acta Orthop 78(5):661–667PubMedCrossRef

38.

Good L, Peterson E, Lisander B (2003) Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth 90(5):596–599PubMedCrossRef

39.

Sehat KR, Evans R, Newman JH (2000) How much blood is really lost in total knee arthroplasty?. Correct blood loss management should take hidden loss into account. Knee 7(3):151–155PubMedCrossRef

Title: Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty
Authors: Doerte Matziolis
Georg Matziolis
Carsten Perka
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: Archives of Orthopaedic and Trauma Surgery / Issue 12/2011
Print ISSN: 0936-8051
Electronic ISSN: 1434-3916
DOI: https://doi.org/10.1007/s00402-011-1335-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty

Abstract

Introduction

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2011

Intra-articular injection of hyaluronic acid (MW 1,500–2,000 kDa; HyalOne®) in symptomatic osteoarthritis of the hip: a prospective cohort study

Insufficiency femoral intertrochanteric fractures associated with greater trochanteric avulsion fractures

Ilizarov hip reconstruction in skeletally mature young patients with chronic unstable hip joints

Erratum to: Locked posterior shoulder dislocation: treatment options and clinical outcomes

Cross-linked ultra-high-molecular weight polyethylene liner and ceramic femoral head in total hip arthroplasty: a prospective study at 5 years follow-up

Rate of avascular necrosis following proximal humerus fractures treated with a lateral locking plate and endosteal implant